These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 7451142)

  • 21. Combined DTIC and cis-dichlorodiammineplatinum(II) therapy for patients with disseminated melanoma: a Northern California Oncology Group study.
    Friedman MA; Kaufman DA; Williams JE; Resser KJ; Rosenbaum EH; Cohen RJ; Glassberg AB; Blume MR; Gershow J; Chan EY
    Cancer Treat Rep; 1979 Mar; 63(3):493-5. PubMed ID: 371802
    [No Abstract]   [Full Text] [Related]  

  • 22. [Dacarbazine in malignant melanoma. Rare, severe side-effect: Budd-Chiari-syndrome (author's transl)].
    Doering C; Pickartz H; Orfanos CE; Altenähr E
    Z Hautkr; 1982 Jul; 57(13):971-80. PubMed ID: 7113323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of advanced malignant melanoma with DTIC].
    Jassem J; Kopacz A; Wojszwiłło-Geppert E
    Pol Tyg Lek; 1979 Feb; 34(8):293-5. PubMed ID: 441041
    [No Abstract]   [Full Text] [Related]  

  • 24. [Phase II study of decarbazine (DTIC) in malignant melanoma. DTIC Research Group].
    Ishihara K
    Gan To Kagaku Ryoho; 1986 May; 13(5):1940-5. PubMed ID: 3707154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
    Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
    Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic implications of the kinetics of immunomodulation during single or combined treatment of melanoma patients with dacarbazine and interferon-alpha.
    Konjević G; Jović V; Radulović S; Jelić S; Dzodić R; Spuzić I
    Neoplasma; 2001; 48(3):175-81. PubMed ID: 11583285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Experience with adjuvant chemoimmunotherapy with DTIC and BCG in malignant melanoma (author's transl)].
    Pullmann H; Muth M
    Z Hautkr; 1982 Feb; 57(4):294-7. PubMed ID: 7080583
    [No Abstract]   [Full Text] [Related]  

  • 28. Influence of therapy on the antioxidant status in patients with melanoma.
    Gadjeva V; Dimov A; Georgieva N
    J Clin Pharm Ther; 2008 Apr; 33(2):179-85. PubMed ID: 18315784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of ICRF-159 versus combination cis-dichlorodiammineplatinum(II) and DTIC in patients with disseminated malignant melanoma.
    Ahmann DL; Edmonson JH; Frytak S; Kvols LK; Bisel HF; Rubin J
    Cancer Treat Rep; 1978 Jan; 62(1):151-3. PubMed ID: 626995
    [No Abstract]   [Full Text] [Related]  

  • 30. [Hypersensitivity to dacarbazine in patients with metastatic malignant melanoma].
    Levy A; Guitera P; Kerob D; Ollivaud L; Archimbaud A; Dubertret L; Basset-Seguin N
    Ann Dermatol Venereol; 2006 Feb; 133(2):157-60. PubMed ID: 16508601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
    Weber JS; Zarour H; Redman B; Trefzer U; O'Day S; van den Eertwegh AJ; Marshall E; Wagner S
    Cancer; 2009 Sep; 115(17):3944-54. PubMed ID: 19536884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase II study evaluating the effect of tamoxifen on DNA repair in melanoma patients treated with dacarbazine.
    Saunders MP; Salisbury AJ; O'Byrne KJ; Souliotis VL; Varcoe SM; Talbot DC; Kyrtopoulos SA; Harris AL
    Anticancer Res; 1997; 17(6D):4677-80. PubMed ID: 9494588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I trial of intermittent high-dose dacarbazine.
    Buesa JM; Gracia M; Valle M; Estrada E; Hidalgo OF; Lacave AJ
    Cancer Treat Rep; 1984 Mar; 68(3):499-504. PubMed ID: 6704980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma.
    Treudler R; Georgieva J; Geilen CC; Orfanos CE
    J Am Acad Dermatol; 2004 May; 50(5):783-5. PubMed ID: 15097966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Dacarbazine (DTIC) therapy and the Budd-Chiari syndrome].
    Balda BR; Bassermann R
    MMW Munch Med Wochenschr; 1980 May; 122(21):792-4. PubMed ID: 6771598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
    Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
    Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single drug and combination chemotherapy in the treatment. Disseminated malignant melanoma.
    Aranha GV; Grage TB
    Minn Med; 1977 Aug; 60(8):543-8. PubMed ID: 882082
    [No Abstract]   [Full Text] [Related]  

  • 38. [Successful therapy of secondary melanoma of the orbit with DTIC].
    Ballin R; Lommatzsch PK; Klöppel R
    Klin Monbl Augenheilkd; 1987 Jul; 191(1):50-2. PubMed ID: 2443753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Combination of fotemustine-dacarbazine and interferon alpha in the treatment of metastatic malignant melanoma].
    Célérier P; Dreno B; Bureau B; Litoux P
    Ann Dermatol Venereol; 1993; 120(6-7):437-40. PubMed ID: 8279787
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Symptoms of occult brain metastases initiated by systemic Dacarbazine (DTIC-DOME) therapy in melanoma patients.
    Hafström L; Jönsson PE
    Clin Oncol; 1980 Dec; 6(4):343-8. PubMed ID: 7460408
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.